MHE Staff

A list of biosimilar competitors to Humira that may come on the market next year.

The partnership will allow international manufacturers to use the technologies for the potential development of COVID-19 vaccines, treatments and diagnostics to benefit people living in low- and middle-income countries.

Jayne Hornung, Chief Clinical Officer, Pharmacy, MMIT addresses the difference between digital therapeutics in the pharmacy and medical benefit space, and digs into the potential causes of the slow uptake in digital therapeutics among payers during this year's Asembia Specialty Pharmacy Summit in Las Vegas.

Doug Long, vice president of Industry Relations at IQVIA spoke on how the current inflationary trend in the economy affects healthcare spending and prices, as well as the trend of specialty drugs accounting for half of the drug spend in healthcare. Hear more of what he shared with our team at this year's Asembia Specialty Pharmacy Summit in Las Vegas.

Jayson Slotnik, partner at Health Policy Strategies, Inc, addresses the most recent developments in value-based contracting and how it affects specialty pharmacy at this year's Asembia Specialty Pharmacy Summit in Las Vegas.

Sonia Oskouei, PharmD, vice president of Biosimilars at Cardinal Health, spoke on pharmacists playing a bigger role in driving biosimilar adoption in 2023 and beyond during Asembia's 2022 Specialty Pharmacy Summit in Las Vegas.

Tracy Russell, senior director of state government affairs at CoverMyMeds addressed what piece of new federal legislation will have the biggest effect on specialty pharmacy and what the Biden administration's emphasis on healthcare equity will do for specialty pharmacy. Russell spoke more on this topic at this year's Asembia Specialty Pharmacy Summit in Las Vegas.

Nearly all employers expect to offer virtual care to meet demand for medical and behavioral health services.

The U.S. Food and Drug Administration expanded the approval of the COVID-19 treatment Veklury (remdesivir) today to include pediatric patients 28 days of age and older.

The company's services will be white labeled under the hospital system’s brand.

Zahra Mahmoudjafari, PharmD, BCOP, clinical pharmacy manager of Hematology/BMT/Cellular Therapeutics at University of Kansas Health System discussed CAR T-Cell therapies in managed care at the annual AMCP 2022 conference in Chicago.

Katie Lockhart, MA, manager of Magellan Health, addresses her AMCP 2022 conference session on the financial impact of specialty drugs and cost-impact models.

Soumya Vishwanath, PharmD, senior manager of Formulary Strategy at Magellan Rx Management, talked about digital therapeutics in the behavioral health space and formulary strategy space during the annual AMCP 2022 conference in Chicago.

Michael Ciarametaro, MBA, National Pharmaceutical Council National discusses gene therapy and the Medicaid Best Price Rule with MHE during the annual AMCP conference in Chicago.

Three thousand people are expected to attend the four-day meeting in Chicago. Kali Cyrus, an assistant professor at Johns Hopkins who identifies as Black, female and queer, is leading a session tomorrow on bias.

Data is shown in a recent American Medical Association survey, which comes as Congress recently extended the availability of telehealth for Medicare patients beyond the current COVID-19 public health emergency.

A recent survey found COVID-19 death rates among both Black and white individuals were higher in areas with more residential segregation, with Black individuals’ death rates being almost twice as high.

Their application to the FDA included data showing that confirmed infections and severe illness were lower among individuals who received a second booster of the Pfizer-BioNTech vaccine.

The FDA issued a complete response letter, so AstraZeneca’s monoclonal antibody won’t be joining Nucala and Dupixent as treatments for chronic rhinosinusitis with nasal polyps anytime soon.

Anthem, which owns Blue Cross Blue Shield plans in 14 states, will need shareholder approval to make the change. The vote is scheduled to occur May 18.

Colorectal cancer disparities between Black and white adults were eliminated among Kaiser Permanente members in Northern California after the healthcare organization instituted a regionwide, structured colorectal cancer screening program.

New report includes research findings on insulin biosimilars use among retail pharmacists and physicians.

The Department of Health and Human Services, through the Health Resources and Services Administration, awarded nearly $55 million to 29 HRSA-funded health centers to increase healthcare access and quality for underserved populations through virtual care such as telehealth, remote patient monitoring, digital patient tools, and health information technology platforms.

The U.S. Food and Drug Administration approved the second COVID-19 vaccine known as Moderna. The approved vaccine will be marketed as Spikevax for the prevention of COVID-19 in individuals 18 years of age and older.

Perfect score from Human Rights Campaign Foundation highlights health company's commitment to LGBTQ+ equality.

A 2022 report by the Department of Labor cites specific examples of health plans and health insurance issuers failing to ensure parity. For instance, a health insurance issuer covered nutritional counseling for medical conditions like diabetes, but not for mental health conditions such as anorexia nervosa, bulimia nervosa and binge-eating disorder.

The global cancer immunotherapy market is set to grow at a compound annual growth rate, or CAGR, of 12.6% to $277.1 billion by 2030.

As the need for rapid tests increase, the nation's largest non-profit patient safety organization evaluated seven COVID-19 rapid tests and found serious gaps in their usability. Results shared that none of the tests were rated as excellent and some had noteworthy usability concerns.

CMS said in a press release that 13.6 million people had enrolled in ACA plans through Healthcare.gov and state-run exchanges.